S3-Leitlinie zum exokrinen Pankreaskarzinom – Kurzversion 2.0 – Dezember 2021, AWMF-Registernummer: 032/010OL

Schlüsselwörter

Pankreaskarzinom - S3 Leitlinie - duktales Adenokarzinom des Pankreas - evidenzbasierte Medizin

Key words

pancreatic cancer - S3 guideline - ductal adenocarcinoma of the pancreas - evidence based medicine

Publication History

Received: 21 January 2022

Accepted: 14 February 2022

Article published online:
07 June 2022

• Literatur

• 1 Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften – Ständige Kommission, L. AWMF-Regelwerk "Leitlinien". 2020 [cited 12.12.2021; Available from: 2. Aufl.. http://www.awmf.org/leitlinien/awmf-regelwerk/awmf-regelwerk.html
• 2 ZfKD and GEKID, Krebs in Deutschland, in Bauchspeicheldrüse, RKI, Editor. 2016
• 3 ZfKD. Krebsarten. 2019 Available from: https://www.krebsdaten.de/Krebs/DE/Content/Krebsarten/krebsarten_node.html
• 4 Fernandez E, La Vecchia C, Decarli A. Attributable risks for pancreatic cancer in northern Italy. Cancer Epidemiol Biomarkers Prev 1996; 5 (01) 23-27
• 5 Ji BT. et al. Dietary factors and the risk of pancreatic cancer: a case-control study in Shanghai China. Cancer Epidemiol Biomarkers Prev 1995; 4 (08) 885-893
• 6 Soler M. et al. Diet, alcohol, coffee and pancreatic cancer: final results from an Italian study. Eur J Cancer Prev 1998; 7 (06) 455-460
• 7 Nkondjock A. et al. Dietary patterns and risk of pancreatic cancer. Int J Cancer 2005; 114 (05) 817-823
• 8 Nothlings U. et al. Meat and fat intake as risk factors for pancreatic cancer: the multiethnic cohort study. J Natl Cancer Inst 2005; 97 (19) 1458-1465
• 9 Glade MJ. Food, nutrition, and the prevention of cancer: a global perspective. American Institute for Cancer Research/World Cancer Research Fund, American Institute for Cancer Research, 1997. Nutrition 1999; 15 (06) 523-526
• 10 Michaud DS. et al. Dietary meat, dairy products, fat, and cholesterol and pancreatic cancer risk in a prospective study. Am J Epidemiol 2003; 157 (12) 1115-1125
• 11 Michaud DS. et al. Dietary patterns and pancreatic cancer risk in men and women. J Natl Cancer Inst 2005; 97 (07) 518-524
• 12 Hine RJ. et al. Nutritional links to plausible mechanisms underlying pancreatic cancer: a conference report. Pancreas 2003; 27 (04) 356-366
• 13 Bueno de Mesquita HB. et al. Intake of foods and nutrients and cancer of the exocrine pancreas: a population-based case-control study in The Netherlands. Int J Cancer 1991; 48 (04) 540-549
• 14 Lyon JL. et al. Dietary intake as a risk factor for cancer of the exocrine pancreas. Cancer Epidemiol Biomarkers Prev 1993; 2 (06) 513-518
• 15 Fraser GE. Associations between diet and cancer, ischemic heart disease, and all-cause mortality in non-Hispanic white California Seventh-day Adventists. Am J Clin Nutr 1999; 70 (03) 532S-538S
• 16 Mills PK. et al. Dietary habits and past medical history as related to fatal pancreas cancer risk among Adventists. Cancer 1988; 61 (12) 2578-2585
• 17 Chan JM, Wang F, Holly EA. Vegetable and fruit intake and pancreatic cancer in a population-based case-control study in the San Francisco bay area. Cancer Epidemiol Biomarkers Prev 2005; 14 (09) 2093-2097
• 18 Negri E. et al. Vegetable and fruit consumption and cancer risk. Int J Cancer 1991; 48 (03) 350-354
• 19 Larsson SC. et al. Fruit and vegetable consumption in relation to pancreatic cancer risk: a prospective study. Cancer Epidemiol Biomarkers Prev 2006; 15 (02) 301-305
• 20 Vainio H, Weiderpass E. Fruit and vegetables in cancer prevention. Nutr Cancer 2006; 54 (01) 111-142
• 21 Stolzenberg-Solomon RZ. et al. Prospective study of diet and pancreatic cancer in male smokers. Am J Epidemiol 2002; 155 (09) 783-792
• 22 Zhang J, Zhao Z, Berkel HJ. Animal fat consumption and pancreatic cancer incidence: evidence of interaction with cigarette smoking. Ann Epidemiol 2005; 15 (07) 500-508
• 23 Lin Y. et al. Nutritional factors and risk of pancreatic cancer: a population-based case-control study based on direct interview in Japan. J Gastroenterol 2005; 40 (03) 297-301
• 24 Anderson KE. et al. Meat intake and cooking techniques: associations with pancreatic cancer. Mutat Res 2002; 506-507: 225-231
• 25 Anderson KE. et al. Dietary intake of heterocyclic amines and benzo(a)pyrene: associations with pancreatic cancer. Cancer Epidemiol Biomarkers Prev 2005; 14 (09) 2261-2265
• 26 Ghadirian P. et al. Food habits and pancreatic cancer: a case-control study of the Francophone community in Montreal, Canada. Cancer Epidemiol Biomarkers Prev 1995; 4 (08) 895-899
• 27 Fernandez E. et al. Fish consumption and cancer risk. Am J Clin Nutr 1999; 70 (01) 85-90
• 28 Michaud DS. et al. Dietary sugar, glycemic load, and pancreatic cancer risk in a prospective study. J Natl Cancer Inst 2002; 94 (17) 1293-1300
• 29 Silvera SA. et al. Glycemic index, glycemic load, and pancreatic cancer risk (Canada). Cancer Causes Control 2005; 16 (04) 431-436
• 30 Schernhammer ES. et al. Sugar-sweetened soft drink consumption and risk of pancreatic cancer in two prospective cohorts. Cancer Epidemiol Biomarkers Prev 2005; 14 (09) 2098-2105
• 31 Lin Y. et al. Risk of pancreatic cancer in relation to alcohol drinking, coffee consumption and medical history: findings from the Japan collaborative cohort study for evaluation of cancer risk. Int J Cancer 2002; 99 (05) 742-746
• 32 Michaud DS. et al. Coffee and alcohol consumption and the risk of pancreatic cancer in two prospective United States cohorts. Cancer Epidemiol Biomarkers Prev 2001; 10 (05) 429-437
• 33 Silverman DT. Risk factors for pancreatic cancer: a case-control study based on direct interviews. Teratog Carcinog Mutagen 2001; 21 (01) 7-25
• 34 Brown LM. Epidemiology of alcohol-associated cancers. Alcohol 2005; 35 (03) 161-168
• 35 Ye W. et al. Alcohol abuse and the risk of pancreatic cancer. Gut 2002; 51 (02) 236-239
• 36 Talamini G. et al. Alcohol and smoking as risk factors in chronic pancreatitis and pancreatic cancer. Dig Dis Sci 1999; 44 (07) 1303-1311
• 37 MacMahon B. et al. Coffee and cancer of the pancreas. N Engl J Med 1981; 304 (11) 630-633
• 38 Gullo L, Pezzilli R, Morselli-Labate AM. Coffee and cancer of the pancreas: an Italian multicenter study. The Italian Pancreatic Cancer Study Group. Pancreas 1995; 11 (03) 223-229
• 39 Lyon JL. et al. Coffee consumption and the risk of cancer of the exocrine pancreas: a case-control study in a low-risk population. Epidemiology 1992; 3 (02) 164-170
• 40 Harnack LJ. et al. Smoking, alcohol, coffee, and tea intake and incidence of cancer of the exocrine pancreas: the Iowa Womenʼs Health Study. Cancer Epidemiol Biomarkers Prev 1997; 6 (12) 1081-1086
• 41 Qiu D. et al. Overview of the epidemiology of pancreatic cancer focusing on the JACC Study. J Epidemiol 2005; 15 (Suppl. 02) S157-S167
• 42 Tavani A, La Vecchia C. Coffee and cancer: a review of epidemiological studies, 1990-1999. Eur J Cancer Prev 2000; 9 (04) 241-256
• 43 La Vecchia C. et al. Tea consumption and cancer risk. Nutr Cancer 1992; 17 (01) 27-31
• 44 Nagano J. et al. A prospective study of green tea consumption and cancer incidence, Hiroshima and Nagasaki (Japan). Cancer Causes Control 2001; 12 (06) 501-508
• 45 Hemminki K, Dong C, Vaittinen P. Cancer risks to spouses and offspring in the Family-Cancer Database. Genet Epidemiol 2001; 20 (02) 247-257
• 46 Hemminki K, Jiang Y. Cancer risks among long-standing spouses. Br J Cancer 2002; 86 (11) 1737-1740
• 47 Nilsen TI, Vatten LJ. A prospective study of lifestyle factors and the risk of pancreatic cancer in Nord-Trondelag, Norway. Cancer Causes Control 2000; 11 (07) 645-652
• 48 Berrington de Gonzalez A, Sweetland S, Spencer E. A meta-analysis of obesity and the risk of pancreatic cancer. Br J Cancer 2003; 89 (03) 519-523
• 49 Michaud DS. et al. Physical activity, obesity, height, and the risk of pancreatic cancer. Jama 2001; 286 (08) 921-929
• 50 Patel AV. et al. Obesity, recreational physical activity, and risk of pancreatic cancer in a large U.S. Cohort. Cancer Epidemiol Biomarkers Prev 2005; 14 (02) 459-466
• 51 Rapp K. et al. Obesity and incidence of cancer: a large cohort study of over 145000 adults in Austria. Br J Cancer 2005; 93 (09) 1062-1067
• 52 Larsson SC. et al. Overall obesity, abdominal adiposity, diabetes and cigarette smoking in relation to the risk of pancreatic cancer in two Swedish population-based cohorts. Br J Cancer 2005; 93 (11) 1310-1315
• 53 Berrington de Gonzalez A. et al. Anthropometry, physical activity, and the risk of pancreatic cancer in the European prospective investigation into cancer and nutrition. Cancer Epidemiol Biomarkers Prev 2006; 15 (05) 879-885
• 54 Silverman DT. et al. Dietary and nutritional factors and pancreatic cancer: a case-control study based on direct interviews. J Natl Cancer Inst 1998; 90 (22) 1710-1719
• 55 Stolzenberg-Solomon RZ. et al. A prospective study of medical conditions, anthropometry, physical activity, and pancreatic cancer in male smokers (Finland). Cancer Causes Control 2002; 13 (05) 417-426
• 56 Hanley AJ. et al. Physical activity, anthropometric factors and risk of pancreatic cancer: results from the Canadian enhanced cancer surveillance system. Int J Cancer 2001; 94 (01) 140-147
• 57 Coughlin SS. et al. Predictors of pancreatic cancer mortality among a large cohort of United States adults. Cancer Causes Control 2000; 11 (10) 915-923
• 58 Lin Y. et al. A prospective cohort study of cigarette smoking and pancreatic cancer in Japan. Cancer Causes Control 2002; 13 (03) 249-254
• 59 Yun YH. et al. Cigarette smoking and cancer incidence risk in adult men: National Health Insurance Corporation Study. Cancer Detect Prev 2005; 29 (01) 15-24
• 60 Chiu BC. et al. Cigarette smoking and risk of bladder, pancreas, kidney, and colorectal cancers in Iowa. Ann Epidemiol 2001; 11 (01) 28-37
• 61 Bonelli L. et al. Exocrine pancreatic cancer, cigarette smoking, and diabetes mellitus: a case-control study in northern Italy. Pancreas 2003; 27 (02) 143-149
• 62 Duell EJ. et al. A population-based, case-control study of polymorphisms in carcinogen-metabolizing genes, smoking, and pancreatic adenocarcinoma risk. J Natl Cancer Inst 2002; 94 (04) 297-306
• 63 Miyasaka K. et al. Inactive aldehyde dehydrogenase-2 increased the risk of pancreatic cancer among smokers in a Japanese male population. Pancreas 2005; 30 (02) 95-98
• 64 Wang L. et al. Genetic polymorphisms in methylenetetrahydrofolate reductase and thymidylate synthase and risk of pancreatic cancer. Clin Gastroenterol Hepatol 2005; 3 (08) 743-751
• 65 Villeneuve PJ. et al. Environmental tobacco smoke and the risk of pancreatic cancer: findings from a Canadian population-based case-control study. Can J Public Health 2004; 95 (01) 32-37
• 66 Alguacil J, Pollan M, Gustavsson P. Occupations with increased risk of pancreatic cancer in the Swedish population. Occup Environ Med 2003; 60 (08) 570-576
• 67 Alguacil J. et al. Occupation and pancreatic cancer in Spain: a case-control study based on job titles. PANKRAS II Study Group. Int J Epidemiol 2000; 29 (06) 1004-1013
• 68 Laakkonen A, Kauppinen T, Pukkala E. Cancer risk among Finnish food industry workers. Int J Cancer 2006; 118 (10) 2567-2571
• 69 Fryzek JP. et al. A case-control study of self-reported exposures to pesticides and pancreas cancer in southeastern Michigan. Int J Cancer 1997; 72 (01) 62-67
• 70 Ji BT. et al. Occupational exposure to pesticides and pancreatic cancer. Am J Ind Med 2001; 39 (01) 92-99
• 71 Ojajarvi IA. et al. Occupational exposures and pancreatic cancer: a meta-analysis. Occup Environ Med 2000; 57 (05) 316-324
• 72 Ojajarvi A. et al. Risk of pancreatic cancer in workers exposed to chlorinated hydrocarbon solvents and related compounds: a meta-analysis. Am J Epidemiol 2001; 153 (09) 841-850
• 73 Weiderpass E. et al. Occupational exposures and gastrointestinal cancers among Finnish women. J Occup Environ Med 2003; 45 (03) 305-315
• 74 Yassi A, Tate RB, Routledge M. Cancer incidence and mortality in workers employed at a transformer manufacturing plant: update to a cohort study. Am J Ind Med 2003; 44 (01) 58-62
• 75 Ji J, Hemminki K. Socioeconomic and occupational risk factors for pancreatic cancer: a cohort study in Sweden. J Occup Environ Med 2006; 48 (03)
• 76 Bjelakovic G. et al. Antioxidant supplements for prevention of gastrointestinal cancers: a systematic review and meta-analysis. Lancet 2004; 364: 1219-1228
• 77 Harris RE. et al. Aspirin, ibuprofen, and other non-steroidal anti-inflammatory drugs in cancer prevention: a critical review of non-selective COX-2 blockade (review). Oncol Rep 2005; 13 (04) 559-583
• 78 Jacobs EJ. et al. Aspirin use and pancreatic cancer mortality in a large United States cohort. J Natl Cancer Inst 2004; 96 (07) 524-528
• 79 Coogan PF. et al. Nonsteroidal anti-inflammatory drugs and risk of digestive cancers at sites other than the large bowel. Cancer Epidemiol Biomarkers Prev 2000; 9 (01) 119-123
• 80 Homma T, Tsuchiya R. The study of the mass screening of persons without symptoms and of the screening of outpatients with gastrointestinal complaints or icterus for pancreatic cancer in Japan, using CA19-9 and elastase-1 or ultrasonography. Int J Pancreatol 1991; 9: 119-124
• 81 Kim JE. et al. Clinical usefulness of carbohydrate antigen 19-9 as a screening test for pancreatic cancer in an asymptomatic population. J Gastroenterol Hepatol 2004; 19 (02) 182-186
• 82 Force U.P.S.T. Screening for Pancreatic Cancer: US Preventive Services Task Force Reaffirmation Recommendation Statement. JAMA 2019; 322 (05) 438-444
• 83 Klein AP. et al. Prospective risk of pancreatic cancer in familial pancreatic cancer kindreds. Cancer Res 2004; 64 (07) 2634-2638
• 84 Bartsch DK. et al. Refinement of screening for familial pancreatic cancer. Gut 2016; 65 (08) 1314-1321
• 85 Goggins M. et al. Management of patients with increased risk for familial pancreatic cancer: updated recommendations from the International Cancer of the Pancreas Screening (CAPS) Consortium. Gut 2019; 69 (01) 7-17
• 86 Tersmette AC. et al. Increased risk of incident pancreatic cancer among first-degree relatives of patients with familial pancreatic cancer. Clin Cancer Res 2001; 7 (03) 738-744
• 87 Stoffel EM. et al. Evaluating susceptibility to pancreatic cancer: ASCO provisional clinical opinion. Journal of Clinical Oncology 2019; 37 (02) 153-164
• 88 Bruenderman EH, Martin RCG. High-risk population in sporadic pancreatic adenocarcinoma: Guidelines for screening. Journal of Surgical Research 2015; 194 (01) 212-219
• 89 Canto MI. et al. Risk of Neoplastic Progression in Individuals at High Risk for Pancreatic Cancer Undergoing Long-term Surveillance. Gastroenterology 2018; 155 (03) 740
• 90 Lilley M, Gilchrist D. The hereditary spectrum of pancreatic cancer: the Edmonton experience. Can J Gastroenterol 2004; 18 (01) 17-21
• 91 Couch FJ. et al. Germ line Fanconi anemia complementation group C mutations and pancreatic cancer. Cancer Res 2005; 65 (02) 383-386
• 92 Howes N. et al. Clinical and genetic characteristics of hereditary pancreatitis in Europe. Clin Gastroenterol Hepatol 2004; 2 (03) 252-261
• 93 Lowenfels AB. et al. Hereditary pancreatitis and the risk of pancreatic cancer.International Hereditary Pancreatitis Study Group. J Natl Cancer Inst 1997; 89 (06) 442-446
• 94 Canto MI. et al. Screening for early pancreatic neoplasia in high-risk individuals: a prospective controlled study. Clin Gastroenterol Hepatol 2006; 4 (06) 766-781
• 95 Canto MI. et al. Screening for pancreatic neoplasia in high-risk individuals: an EUS-based approach. Clin Gastroenterol Hepatol 2004; 2 (07) 606-621
• 96 Brentnall TA. Management strategies for patients with hereditary pancreatic cancer. Curr Treat Options Oncol 2005; 6 (05) 437-445
• 97 Kimmey MB. et al. Screening and surveillance for hereditary pancreatic cancer. Gastrointest Endosc 2002; 56 (04) S82-S86
• 98 Bansal P, Sonnenberg A. Pancreatitis is a risk factor for pancreatic cancer. Gastroenterology 1995; 109 (01) 247-251
• 99 Karlson BM. et al. The risk of pancreatic cancer following pancreatitis: an association due to confounding?. Gastroenterology 1997; 113 (02) 587-592
• 100 Lowenfels AB. et al. Pancreatitis and the risk of pancreatic cancer.International Pancreatitis Study Group. N Engl J Med 1993; 328 (20) 1433-1437
• 101 Malka D. et al. Risk of pancreatic adenocarcinoma in chronic pancreatitis. Gut 2002; 51 (06) 849-852
• 102 Talamini G. et al. Incidence of cancer in the course of chronic pancreatitis. Am J Gastroenterol 1999; 94 (05) 1253-1260
• 103 Gullo L, Pezzilli R, Morselli-Labate AM. Diabetes and the risk of pancreatic cancer. Italian Pancreatic Cancer Study Group. N Engl J Med 1994; 331 (02) 81-84
• 104 Rousseau MC. et al. Diabetes mellitus and cancer risk in a population-based case-control study among men from Montreal, Canada. Int J Cancer 2006; 118 (08) 2105-2109
• 105 Coughlin SS. et al. Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults. Am J Epidemiol 2004; 159 (12) 1160-1167
• 106 Huxley R. et al. Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies. Br J Cancer 2005; 92 (11) 2076-2083
• 107 Stolzenberg-Solomon RZ. et al. Insulin, glucose, insulin resistance, and pancreatic cancer in male smokers. Jama 2005; 294 (22) 2872-2878
• 108 Wideroff L. et al. Cancer incidence in a population-based cohort of patients hospitalized with diabetes mellitus in Denmark. J Natl Cancer Inst 1997; 89 (18) 1360-1365
• 109 Calle EE. et al. Diabetes mellitus and pancreatic cancer mortality in a prospective cohort of United States adults. Cancer Causes Control 1998; 9 (04) 403-410
• 110 Chow WH. et al. Risk of pancreatic cancer following diabetes mellitus: a nationwide cohort study in Sweden. J Natl Cancer Inst 1995; 87 (12) 930-931
• 111 Silverman DT. et al. Diabetes mellitus, other medical conditions and familial history of cancer as risk factors for pancreatic cancer. Br J Cancer 1999; 80 (11) 1830-1837
• 112 Everhart J, Wright D. Diabetes mellitus as a risk factor for pancreatic cancer. A meta-analysis. Jama 1995; 273 (20) 1605-1609
• 113 Chari ST. et al. Probability of pancreatic cancer following diabetes: a population-based study. Gastroenterology 2005; 129 (02) 504-511
• 114 rBjornsson E. et al. Severe jaundice in Sweden in the new millennium: causes, investigations, treatment and prognosis. Scand J Gastroenterol 2003; 38 (01) 86-94
• 115 Reisman Y. et al. Clinical presentation of (subclinical) jaundice – the Euricterus project in The Netherlands. United Dutch Hospitals and Euricterus Project Management Group. Hepatogastroenterology 1996; 43 (11) 1190-1195
• 116 Watanabe I. et al. Onset symptoms and tumor locations as prognostic factors of pancreatic cancer. Pancreas 2004; 28 (02) 160-165
• 117 Balthazar EJ. Pancreatitis associated with pancreatic carcinoma. Preoperative diagnosis: role of CT imaging in detection and evaluation. Pancreatology 2005; 5 (04) 330-344
• 118 Mujica VR, Barkin JS, Go VL. Acute pancreatitis secondary to pancreatic carcinoma. Study Group Participants. Pancreas 2000; 21 (04) 329-332
• 119 Adamek HE. et al. Pancreatic cancer detection with magnetic resonance cholangiopancreatography and endoscopic retrograde cholangiopancreatography: a prospective controlled study. Lancet 2000; 356: 190-193
• 120 Hanninen EL. et al. Magnetic resonance cholangiopancreatography: image quality, ductal morphology, and value of additional T2- and T1-weighted sequences for the assessment of suspected pancreatic cancer. Acta Radiol 2005; 46 (02) 117-125
• 121 Forsmark CE, Lambiase L, Vogel SB. Diagnosis of pancreatic cancer and prediction of unresectability using the tumor-associated antigen CA19-9. Pancreas 1994; 9 (06) 731-734
• 122 Nazli O. et al. The diagnostic importance of CEA and CA 19-9 for the early diagnosis of pancreatic carcinoma. Hepatogastroenterology 2000; 47 (36) 1750-1752
• 123 Ritts Jr RE. et al. Comparison of preoperative serum CA19-9 levels with results of diagnostic imaging modalities in patients undergoing laparotomy for suspected pancreatic or gallbladder disease. Pancreas 1994; 9 (06) 707-716
• 124 Tessler DA. et al. Predictors of cancer in patients with suspected pancreatic malignancy without a tissue diagnosis. Am J Surg 2006; 191 (02) 191-197
• 125 Agarwal B. et al. Endoscopic ultrasound-guided fine needle aspiration and multidetector spiral CT in the diagnosis of pancreatic cancer. Am J Gastroenterol 2004; 99 (05) 844-850
• 126 Klapman JB. et al. Negative predictive value of endoscopic ultrasound in a large series of patients with a clinical suspicion of pancreatic cancer. Am J Gastroenterol 2005; 100 (12) 2658-2661
• 127 Varadarajulu S, Wallace MB. Applications of endoscopic ultrasonography in pancreatic cancer. Cancer Control 2004; 11 (01) 15-22
• 128 David O. et al. Pancreatic masses: a multi-institutional study of 364 fine-needle aspiration biopsies with histopathologic correlation. Diagn Cytopathol 1998; 19 (06) 423-427
• 129 Bipat S. et al. Ultrasonography, computed tomography and magnetic resonance imaging for diagnosis and determining resectability of pancreatic adenocarcinoma: a meta-analysis. J Comput Assist Tomogr 2005; 29 (04) 438-445
• 130 James PD. et al. The incremental benefit of EUS for identifying unresectable disease among adults with pancreatic adenocarcinoma: A meta-analysis. PLoS One 2017; 12 (03) e0173687
• 131 Krishna S. et al. Diagnostic performance of endoscopic ultrasound for detection of pancreatic malignancy following an indeterminate multidetector CT scan: a systemic review and meta-analysis. Surgical Endoscopy 2017; 31 (11) 4558-4567
• 132 Chew C, OʼDwyer PJ. The value of liver magnetic resonance imaging in patients with findings of resectable pancreatic cancer on computed tomography. Singapore Medical Journal 2016; 57 (06) 334-338
• 133 Ito T. et al. The diagnostic advantage of EOB-MR imaging over CT in the detection of liver metastasis in patients with potentially resectable pancreatic cancer. Pancreatology 2017; 17 (03) 451-456
• 134 Jeon SK. et al. Magnetic resonance with diffusion-weighted imaging improves assessment of focal liver lesions in patients with potentially resectable pancreatic cancer on CT. European Radiology 2018; 28 (08) 3484-3493
• 135 Kim HJ. et al. Incremental Role of Pancreatic Magnetic Resonance Imaging after Staging Computed Tomography to Evaluate Patients with Pancreatic Ductal Adenocarcinoma. Cancer Res Treat 2019; 51 (01) 24-33
• 136 Kim HW. et al. Adjunctive role of preoperative liver magnetic resonance imaging for potentially resectable pancreatic cancer. Surgery (United States) 2017; 161 (06) 1579-1587
• 137 Wang L. et al. Positron emission tomography modalities prevent futile radical resection of pancreatic cancer: A meta-analysis. International Journal of Surgery 2017; 46: 119-125
• 138 Ghaneh P. et al. PET-PANC: multicentre prospective diagnostic accuracy and health economic analysis study of the impact of combined modality 18fluorine-2-fluoro-2-deoxy-d-glucose positron emission tomography with computed tomography scanning in the diagnosis and management of pancreatic cancer. Health technology assessment (Winchester, England) 2018; 22 (07) 1-114
• 139 Toft J. et al. Imaging modalities in the diagnosis of pancreatic adenocarcinoma: A systematic review and meta-analysis of sensitivity, specificity and diagnostic accuracy. Eur J Radiol 2017; 92: 17-23
• 140 Schachter PP. et al. The impact of laparoscopy and laparoscopic ultrasonography on the management of pancreatic cancer. Arch Surg 2000; 135 (11) 1303-1307
• 141 Vollmer CM. et al. Utility of staging laparoscopy in subsets of peripancreatic and biliary malignancies. Ann Surg 2002; 235 (01) 1-7
• 142 European Study Group on Cystic Tumours of the, P. European evidence-based guidelines on pancreatic cystic neoplasms. Gut 2018; 67: 789-804
• 143 Tanaka M. et al. Revisions of international consensus Fukuoka guidelines for the management of IPMN of the pancreas. Pancreatology 2017; 17 (05) 738-753
• 144 Beyer G. et al. Management Algorithm for Cystic Pancreatic Lesions. Visc Med 2018; 34 (03) 197-201
• 145 Doi R. et al. Surgery versus radiochemotherapy for resectable locally invasive pancreatic cancer: final results of a randomized multi-institutional trial. Surg Today 2008; 38 (11) 1021-1028
• 146 Schwarz RE. Technical considerations to maintain a low frequency of postoperative biliary stent-associated infections. J Hepatobiliary Pancreat Surg 2002; 9 (01) 93-97
• 147 Gerke H. et al. Complications of pancreaticoduodenectomy after neoadjuvant chemoradiation in patients with and without preoperative biliary drainage. Dig Liver Dis 2004; 36 (06) 412-418
• 148 Jagannath P. et al. Effect of preoperative biliary stenting on immediate outcome after pancreaticoduodenectomy. Br J Surg 2005; 92 (03) 356-361
• 149 Martignoni ME. et al. Effect of preoperative biliary drainage on surgical outcome after pancreatoduodenectomy. Am J Surg 2001; 181 (01) 52-59
• 150 Sohn TA. et al. Do preoperative biliary stents increase postpancreaticoduodenectomy complications?. J Gastrointest Surg 2000; 4 (03) 258-267
• 151 van der Gaag NA. et al. Preoperative biliary drainage for cancer of the head of the pancreas. N Engl J Med 2010; 362 (02) 129-137
• 152 Barabino M. et al. Is there still a role for laparoscopy combined with laparoscopic ultrasonography in the staging of pancreatic cancer?. Surg Endosc 2011; 25 (01) 160-165
• 153 Contreras CM. et al. Staging laparoscopy enhances the detection of occult metastases in patients with pancreatic adenocarcinoma. J Surg Oncol 2009; 100 (08) 663-669
• 154 Doucas H. et al. Assessment of pancreatic malignancy with laparoscopy and intraoperative ultrasound. Surg Endosc 2007; 21 (07) 1147-1152
• 155 Enestvedt CK. et al. Diagnostic laparoscopy for patients with potentially resectable pancreatic adenocarcinoma: is it cost-effective in the current era?. J Gastrointest Surg 2008; 12 (07) 1177-1184
• 156 Hariharan D. et al. The role of laparoscopy and laparoscopic ultrasound in the preoperative staging of pancreatico-biliary cancers--A meta-analysis. Eur J Surg Oncol 2010; 36 (10) 941-948
• 157 Mayo SC. et al. Evolving preoperative evaluation of patients with pancreatic cancer: does laparoscopy have a role in the current era?. J Am Coll Surg 2009; 208 (01) 87-95
• 158 Muntean V. et al. Staging laparoscopy in digestive cancers. J Gastrointestin Liver Dis 2009; 18 (04) 461-467
• 159 Satoi S. et al. Selective use of staging laparoscopy based on carbohydrate antigen 19-9 level and tumor size in patients with radiographically defined potentially or borderline resectable pancreatic cancer. Pancreas 2011; 40 (03) 426-432
• 160 Shah D. et al. Preoperative prediction of complete resection in pancreatic cancer. J Surg Res 2008; 147 (02) 216-220
• 161 White R. et al. Current utility of staging laparoscopy for pancreatic and peripancreatic neoplasms. J Am Coll Surg 2008; 206 (03) 445-450
• 162 Kelly KJ. et al. Prognostic impact of RT-PCR-based detection of peritoneal micrometastases in patients with pancreatic cancer undergoing curative resection. Ann Surg Oncol 2009; 16 (12) 3333-3339
• 163 Yamada S. et al. Clinical implications of peritoneal cytology in potentially resectable pancreatic cancer: positive peritoneal cytology may not confer an adverse prognosis. Ann Surg 2007; 246 (02) 254-258
• 164 Wagner M. et al. Curative resection is the single most important factor determining outcome in patients with pancreatic adenocarcinoma. Br J Surg 2004; 91 (05) 586-594
• 165 Fusai G. et al. Outcome of R1 resection in patients undergoing pancreatico-duodenectomy for pancreatic cancer. Eur J Surg Oncol 2008; 34 (12) 1309-1315
• 166 Gaedcke J. et al. The mesopancreas is the primary site for R1 resection in pancreatic head cancer: relevance for clinical trials. Langenbecks Arch Surg 2010; 395 (04) 451-458
• 167 Hartwig W. et al. Pancreatic cancer surgery in the new millennium: better prediction of outcome. Ann Surg 2011; 254 (02) 311-319
• 168 Esposito I. et al. Most pancreatic cancer resections are R1 resections. Ann Surg Oncol 2008; 15 (06) 1651-1660
• 169 Raut CP. et al. Impact of resection status on pattern of failure and survival after pancreaticoduodenectomy for pancreatic adenocarcinoma. Ann Surg 2007; 246 (01) 52-60
• 170 Chang DK. et al. Margin Clearance and Outcome in Resected Pancreatic Cancer. Journal of Clinical Oncology 2009; 27 (17) 2855-2862
• 171 Campbell F. et al. Classification of R1 resections for pancreatic cancer: the prognostic relevance of tumour involvement within 1 mm of a resection margin. Histopathology 2009; 55 (03) 277-283
• 172 Jamieson NB. et al. Positive mobilization margins alone do not influence survival following pancreatico-duodenectomy for pancreatic ductal adenocarcinoma. Ann Surg 2010; 251 (06) 1003-1010
• 173 Diener MarkusK. et al. Pylorus-preserving pancreaticoduodenectomy (pp Whipple) versus pancreaticoduodenectomy (classic Whipple) for surgical treatment of periampullary and pancreatic carcinoma. Cochrane Database of Systematic Reviews 2011;
• 174 Kawai M. et al. Pylorus ring resection reduces delayed gastric emptying in patients undergoing pancreatoduodenectomy: a prospective, randomized, controlled trial of pylorus-resecting versus pylorus-preserving pancreatoduodenectomy. Annals of surgery 2011; 495-501
• 175 Verbeke CS. Resection margins and R1 rates in pancreatic cancer – are we there yet?. Histopathology 2008; 52 (07) 787-796
• 176 Wittekind C. et al. A uniform residual tumor (R) classification: integration of the R classification and the circumferential margin status. Cancer 2009; 115 (15) 3483-3488
• 177 Gajda M, Kenig J. Treatment outcomes of pancreatic cancer in the elderly – literature review. Folia medica Cracoviensia 2018; 58 (03) 49-66
• 178 Kim SY. et al. The outcomes of pancreaticoduodenectomy in patients aged 80 or older: a systematic review and meta-analysis. HPB (Oxford) 2017; 19 (06) 475-482
• 179 Sukharamwala P. et al. Advanced age is a risk factor for post-operative complications and mortality after a pancreaticoduodenectomy: a meta-analysis and systematic review. HPB (Oxford) 2012; 14 (10) 649-657
• 180 van der Geest LG. et al. Elderly Patients Strongly Benefit from Centralization of Pancreatic Cancer Surgery: A Population-Based Study. Ann Surg Oncol 2016; 23 (06) 2002-2009
• 181 van der Geest LG. et al. Pancreatic cancer surgery in elderly patients: Balancing between short-term harm and long-term benefit. A population-based study in the Netherlands. Acta Oncol 2016; 55 (03) 278-285
• 182 Sho M. et al. Prognosis after surgical treatment for pancreatic cancer in patients aged 80 years or older: a multicenter study. J Hepatobiliary Pancreat Sci 2016; 23 (03) 188-197
• 183 Shirai Y. et al. Assessment of Surgical Outcome After Pancreatic Resection in Extremely Elderly Patients. Anticancer Res 2016; 36 (04) 2011-2017
• 184 Sahakyan MA. et al. Perioperative outcomes and survival in elderly patients undergoing laparoscopic distal pancreatectomy. J Hepatobiliary Pancreat Sci 2017; 24 (01) 42-48
• 185 Renz BW. et al. Pancreaticoduodenectomy for adenocarcinoma of the pancreatic head is justified in elderly patients: A Retrospective Cohort Study. Int J Surg 2016; 28: 118-125
• 186 Miyazaki Y. et al. Age does not affect complications and overall survival rate after pancreaticoduodenectomy: Single-center experience and systematic review of literature. Biosci Trends 2016; 10 (04) 300-306
• 187 Hsu CC. et al. Early mortality risk score: identification of poor outcomes following upfront surgery for resectable pancreatic cancer. J Gastrointest Surg 2012; 16 (04) 753-761
• 188 He W. et al. Underuse of surgical resection among elderly patients with early-stage pancreatic cancer. Surgery 2015; 158 (05) 1226-1234
• 189 Ansari D. et al. Safety of pancreatic resection in the elderly: a retrospective analysis of 556 patients. Ann Gastroenterol 2016; 29 (02) 221-225
• 190 Addeo P. et al. Pancreatic fistula after a pancreaticoduodenectomy for ductal adenocarcinoma and its association with morbidity: a multicentre study of the French Surgical Association. HPB (Oxford) 2014; 16 (01) 46-55
• 191 Lyu HG. et al. Risk Factors of Reoperation After Pancreatic Resection. Dig Dis Sci 2017; 62 (06) 1666-1675
• 192 Turrini O. et al. Pancreatectomy for adenocarcinoma in elderly patients: Postoperative outcomes and long term results: A study of the French Surgical Association. European Journal of Surgical Oncology 2013; 39 (02) 171-178
• 193 Tas F. et al. Performance status of patients is the major prognostic factor at all stages of pancreatic cancer. Int J Clin Oncol 2013; 18 (05) 839-846
• 194 Kleeff J. et al. The impact of diabetes mellitus on survival following resection and adjuvant chemotherapy for pancreatic cancer. Br J Cancer 2016; 115 (07) 887-894
• 195 Feyko J. et al. Pancreatectomy in Patients with Impaired Renal Function: How Risky Is It?. Am Surg 2016; 82 (01) 16-21
• 196 Isaji S. et al. International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017. Pancreatology 2018; 18 (01) 2-11
• 197 Khorana AA. et al. Potentially Curable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol 2016; 34 (21) 2541-2556
• 198 Persigehl T. et al. Structured Reporting of Solid and Cystic Pancreatic Lesions in CT and MRI: Consensus-Based Structured Report Templates of the German Society of Radiology (DRG). Rofo 2020; 192 (07) 641-656
• 199 Agalianos C. et al. Positive para-aortic lymph nodes following pancreatectomy for pancreatic cancer. Systematic review and meta-analysis of impact on short term survival and association with clinicopathologic features. HPB 2016; 18 (08) 633-641
• 200 Cao F. et al. Prognostic significance of positive peritoneal cytology in resectable pancreatic cancer: A systemic review and metaanalysis. Oncotarget 2017; 8 (09) 15004-15013
• 201 Gebauer F, Damanakis AI, Bruns C. [Oligometastasis in pancreatic cancer : Current state of knowledge and spectrum of local therapy]. Chirurg 2018; 89 (07) 510-515
• 202 Michalski CW. et al. Resection of primary pancreatic cancer and liver metastasis: a systematic review. Dig Surg 2008; 25 (06) 473-480
• 203 Crippa S. et al. Is there a role for surgical resection in patients with pancreatic cancer with liver metastases responding to chemotherapy?. European Journal of Surgical Oncology 2016; 42 (10) 1533-1539
• 204 Hempel S. et al. Para-aortic lymph node metastases in pancreatic cancer should not be considered a watershed for curative resection. Scientific reports 2017; 7 (01) 7688
• 205 Kim Y. et al. Improved survival after palliative resection of unsuspected stage IV pancreatic ductal adenocarcinoma. HPB 2016; 18 (04) 325-331
• 206 Klaiber U. et al. Prognostic Factors of Survival After Neoadjuvant Treatment and Resection for Initially Unresectable Pancreatic Cancer. Annals of surgery, 2019.
• 207 Lowder CY. et al. Clinical Implications of Extensive Lymph Node Metastases for Resected Pancreatic Cancer. Annals of Surgical Oncology 2018; 25 (13) 4004-4011
• 208 Philips P. et al. The role of hepatic artery lymph node in pancreatic adenocarcinoma: prognostic factor or a selection criterion for surgery. HPB : the official journal of the International Hepato Pancreato Biliary Association 2014; 16 (12) 1051-1055
• 209 Shi HJ, Jin C, Fu DL. Preoperative evaluation of pancreatic ductal adenocarcinoma with synchronous liver metastasis: Diagnosis and assessment of unresectability. World Journal of Gastroenterology 2016; 22 (45) 10024-10037
• 210 Tachezy M. et al. Synchronous resections of hepatic oligometastatic pancreatic cancer: Disputing a principle in a time of safe pancreatic operations in a retrospective multicenter analysis. Surgery (United States) 2016; 160 (01) 136-144
• 211 Gleisner AL. et al. Is resection of periampullary or pancreatic adenocarcinoma with synchronous hepatic metastasis justified?. Cancer 2007; 110 (11) 2484-2492
• 212 Shrikhande SV. et al. Pancreatic resection for M1 pancreatic ductal adenocarcinoma. Ann Surg Oncol 2007; 14 (01) 118-127
• 213 Takada T. et al. Simultaneous hepatic resection with pancreato-duodenectomy for metastatic pancreatic head carcinoma: does it improve survival?. Hepatogastroenterology 1997; 44 (14) 567-573
• 214 Massucco P. et al. Prognostic significance of lymph node metastases in pancreatic head cancer treated with extended lymphadenectomy: not just a matter of numbers. Ann Surg Oncol 2009; 16 (12) 3323-3332
• 215 Doi R. et al. Prognostic implication of para-aortic lymph node metastasis in resectable pancreatic cancer. World J Surg 2007; 31 (01) 147-154
• 216 Kanda M. et al. Pattern of lymph node metastasis spread in pancreatic cancer. Pancreas 2011; 40 (06) 951-955
• 217 Cordera F. et al. Significance of common hepatic artery lymph node metastases during pancreaticoduodenectomy for pancreatic head adenocarcinoma. Ann Surg Oncol 2007; 14 (08) 2330-2336
• 218 Yamada S. et al. Pancreatic cancer with paraaortic lymph node metastasis: a contraindication for radical surgery?. Pancreas 2009; 38 (01) e13-e17
• 219 Tao L. et al. Surgical resection of a primary tumor improves survival of metastatic pancreatic cancer: A population-based study. Cancer Management and Research 2017; 9: 471-479
• 220 Liu X. et al. Predictors of distant metastasis on exploration in patients with potentially resectable pancreatic cancer. BMC Gastroenterology 2018; 18 (01) 168
• 221 Schwarz M. et al. Efficacy of oral ofloxacin for single-dose perioperative prophylaxis in general surgery--a controlled randomized clinical study. Langenbecks Arch Surg 2001; 386 (06) 397-401
• 222 Targarona EM. et al. Single-dose antibiotic prophylaxis in patients at high risk for infection in biliary surgery: a prospective and randomized study comparing cefonicid with mezlocillin. Surgery 1990; 107 (03) 327-334
• 223 Kujath P. et al. [Current perioperative antibiotic prophylaxis]. Chirurg 2006; 77 (06) 492-498
• 224 Barnett SP. et al. Octreotide does not prevent postoperative pancreatic fistula or mortality following Pancreaticoduodenectomy. Am Surg 2004; 70 (03) 222-226
• 225 Friess H. Buchler MW. Efficacy of somatostatin and its analogues in pancreatic surgery and pancreatic disorders. Digestion 1996; 57 (Suppl. 01) 97-102
• 226 Gouillat C. et al. Randomized controlled multicentre trial of somatostatin infusion after pancreaticoduodenectomy. Br J Surg 2001; 88 (11) 1456-1462
• 227 Hesse UJ. et al. Prospectively randomized trial using perioperative low-dose octreotide to prevent organ-related and general complications after pancreatic surgery and pancreatico-jejunostomy. World J Surg 2005; 29 (10) 1325-1328
• 228 Montorsi M. et al. Efficacy of octreotide in the prevention of pancreatic fistula after elective pancreatic resections: a prospective, controlled, randomized clinical trial. Surgery 1995; 117 (01) 26-31
• 229 Pederzoli P. et al. Efficacy of octreotide in the prevention of complications of elective pancreatic surgery. Italian Study Group. Br J Surg 1994; 81 (02) 265-269
• 230 Yeo CJ. et al. Does prophylactic octreotide decrease the rates of pancreatic fistula and other complications after pancreaticoduodenectomy? Results of a prospective randomized placebo-controlled trial. Ann Surg 2000; 232 (03) 419-429
• 231 Connor S. et al. Meta-analysis of the value of somatostatin and its analogues in reducing complications associated with pancreatic surgery. Br J Surg 2005; 92 (09) 1059-1067
• 232 Warshaw AL. Implications of peritoneal cytology for staging of early pancreatic cancer. Am J Surg 1991; 161 (01) 26-29
• 233 Heeckt P. et al. [Free intraperitoneal tumors cells in pancreatic cancer--significance for clinical course and therapy]. Chirurg 1992; 63 (07) 563-567
• 234 Kinoshita T. et al. [Effectiveness of intraoperative cytological examination of peritoneal washings for patients with pancreatic cancer]. Nihon Geka Gakkai Zasshi 1992; 93 (11) 1410-1415
• 235 Makary MA. et al. Implications of peritoneal cytology for pancreatic cancer management. Arch Surg 1998; 133 (04) 361-365
• 236 Konishi M. et al. Prognostic value of cytologic examination of peritoneal washings in pancreatic cancer. Arch Surg 2002; 137 (04) 475-480
• 237 Nakao A. et al. Peritoneal washings cytology combined with immunocytochemical staining in pancreatic cancer. Hepatogastroenterology 1999; 46 (29) 2974-2977
• 238 Yachida S. et al. Implications of peritoneal washing cytology in patients with potentially resectable pancreatic cancer. Br J Surg 2002; 89 (05) 573-578
• 239 Bachellier P. et al. Is pancreaticoduodenectomy with mesentericoportal venous resection safe and worthwhile?. Am J Surg 2001; 182 (02) 120-129
• 240 Bassi C. et al. Influence of surgical resection and post-operative complications on survival following adjuvant treatment for pancreatic cancer in the ESPAC-1 randomized controlled trial. Dig Surg 2005; 22 (05) 353-363
• 241 Capussotti L. et al. Extended lymphadenectomy and vein resection for pancreatic head cancer: outcomes and implications for therapy. Arch Surg 2003; 138 (12) 1316-1322
• 242 Farnell MB. et al. A prospective randomized trial comparing standard pancreatoduodenectomy with pancreatoduodenectomy with extended lymphadenectomy in resectable pancreatic head adenocarcinoma. Surgery 2005; 138 (04) 618-628
• 243 Fernandez-del CastilloC, Rattner DW, Warshaw AL. Standards for pancreatic resection in the 1990s. Arch Surg 1995; 130 (03) 295-299
• 244 Hartel M. et al. Benefit of venous resection for ductal adenocarcinoma of the pancreatic head. Eur J Surg 2002; 168 (12) 707-712
• 245 Ishikawa O. et al. Practical grouping of positive lymph nodes in pancreatic head cancer treated by an extended pancreatectomy. Surgery 1997; 121 (03) 244-249
• 246 Jurowich C. et al. [Portal vein resection in the framework of surgical therapy of pancreatic head carcinoma: clarification of indication by improved preoperative diagnostic procedures?]. Chirurg 2000; 71 (07) 803-807
• 247 Kawarada Y. et al. Modified standard pancreaticoduodenectomy for the treatment of pancreatic head cancer. Digestion 1999; 60 (Suppl. 01) 120-125
• 248 Klempnauer J. et al. Extended resections of ductal pancreatic cancer--impact on operative risk and prognosis. Oncology 1996; 53 (01) 47-53
• 249 Klinkenbijl JH. et al. The advantages of pylorus-preserving pancreatoduodenectomy in malignant disease of the pancreas and periampullary region. Ann Surg 1992; 216 (02) 142-145
• 250 Kremer B. et al. Surgical possibilities for pancreatic cancer: extended resection. Ann Oncol 1999; 10 (Suppl. 04) 252-256
• 251 Lin PW. et al. Pancreaticoduodenectomy for pancreatic head cancer: PPPD versus Whipple procedure. Hepatogastroenterology 2005; 52 (65) 1601-1604
• 252 Lygidakis NJ. et al. Mono-bloc total spleno-pancreaticoduodenectomy for pancreatic head carcinoma with portal-mesenteric venous invasion. A prospective randomized study. Hepatogastroenterology 2004; 51 (56) 427-433
• 253 Mu DQ, Peng SY, Wang GF. Extended radical operation of pancreatic head cancer: appraisal of its clinical significance. World J Gastroenterol 2005; 11 (16) 2467-2471
• 254 Nakao A. et al. Extended radical resection versus standard resection for pancreatic cancer: the rationale for extended radical resection. Pancreas 2004; 28 (03) 289-292
• 255 Pedrazzoli S. et al. Standard versus extended lymphadenectomy associated with pancreatoduodenectomy in the surgical treatment of adenocarcinoma of the head of the pancreas: a multicenter, prospective, randomized study. Lymphadenectomy Study Group. Ann Surg 1998; 228 (04) 508-517
• 256 Roher HD, Heise JW, Goretzki PE. [Stomach saving duodenopancreatectomy. Indications and contraindications. The most important surgical steps]. Zentralbl Chir 2000; 125 (12) 961-965
• 257 Schafer M, Mullhaupt B, Clavien PA. Evidence-based pancreatic head resection for pancreatic cancer and chronic pancreatitis. Ann Surg 2002; 236 (02) 137-148
• 258 Takada T. et al. Results of a pylorus-preserving pancreatoduodenectomy for pancreatic cancer: a comparison with results of the Whipple procedure. Hepatogastroenterology 1997; 44 (18) 1536-1540
• 259 Tran KT. et al. Pylorus preserving pancreaticoduodenectomy versus standard Whipple procedure: a prospective, randomized, multicenter analysis of 170 patients with pancreatic and periampullary tumors. Ann Surg 2004; 240 (05) 738-745
• 260 Tseng JF. et al. Pancreaticoduodenectomy with vascular resection: margin status and survival duration. J Gastrointest Surg 2004; 8 (08) 935-949
• 261 Zerbi A. et al. Comparison between pylorus-preserving and Whipple pancreatoduodenectomy. Br J Surg 1995; 82 (07) 975-979
• 262 Diener MK. et al. A systematic review and meta-analysis of pylorus-preserving versus classical pancreaticoduodenectomy for surgical treatment of periampullary and pancreatic carcinoma. Ann Surg 2007; 245 (02) 187-200
• 263 Christein JD. et al. Distal pancreatectomy for resectable adenocarcinoma of the body and tail of the pancreas. J Gastrointest Surg 2005; 9 (07) 922-927
• 264 Gebhardt C, Meyer W, Jurowich C. [Is resection of left-sided ductal pancreatic carcinoma of value?]]. Zentralbl Chir 2000; 125 (12) 966-969
• 265 Kayahara M. et al. Distal pancreatectomy--does it have a role for pancreatic body and tail cancer. Hepatogastroenterology 1998; 45 (21) 827-832
• 266 Mayumi T. et al. Distal pancreatectomy with en bloc resection of the celiac artery for carcinoma of the body and tail of the pancreas. Int J Pancreatol 1997; 22 (01) 15-21
• 267 Shimada K. et al. Prognostic factors after distal pancreatectomy with extended lymphadenectomy for invasive pancreatic adenocarcinoma of the body and tail. Surgery 2006; 139 (03) 288-295
• 268 Shoup M. et al. Is extended resection for adenocarcinoma of the body or tail of the pancreas justified?. J Gastrointest Surg 2003; 7 (08) 946-952
• 269 Kondo S. et al. Results of radical distal pancreatectomy with en bloc resection of the celiac artery for locally advanced cancer of the pancreatic body. Langenbecks Arch Surg 2003; 388 (02) 101-106
• 270 Garcea G. et al. Tumour characteristics predictive of survival following resection for ductal adenocarcinoma of the head of pancreas. Eur J Surg Oncol 2007; 33 (07) 892-897
• 271 Murakami Y. et al. Prognostic impact of para-aortic lymph node metastasis in pancreatic ductal adenocarcinoma. World J Surg 2010; 34 (08) 1900-1907
• 272 Pai RK. et al. Pattern of lymph node involvement and prognosis in pancreatic adenocarcinoma: direct lymph node invasion has similar survival to node-negative disease. Am J Surg Pathol 2011; 35 (02) 228-234
• 273 Sahin TT. et al. Prognostic Implications of Lymph Node Metastases in Carcinoma of the Body and Tail of the Pancreas. Pancreas 2011.
• 274 Bhatti I. et al. Lymph node ratio versus number of affected lymph nodes as predictors of survival for resected pancreatic adenocarcinoma. World J Surg 2010; 34 (04) 768-775
• 275 Hellan M. et al. The impact of lymph node number on survival in patients with lymph node-negative pancreatic cancer. Pancreas 2008; 37 (01) 19-24
• 276 House MG. et al. Prognostic significance of pathologic nodal status in patients with resected pancreatic cancer. J Gastrointest Surg 2007; 11 (11) 1549-1555
• 277 Konstantinidis IT. et al. Does the mechanism of lymph node invasion affect survival in patients with pancreatic ductal adenocarcinoma?. J Gastrointest Surg 2010; 14 (02) 261-267
• 278 La Torre M. et al. Role of the Lymph node ratio in pancreatic ductal adenocarcinoma. Impact on patient stratification and prognosis. Journal of Surgical Oncology 2011.
• 279 Murakami Y. et al. Number of metastatic lymph nodes, but not lymph node ratio, is an independent prognostic factor after resection of pancreatic carcinoma. J Am Coll Surg 2010; 211 (02) 196-204
• 280 Pawlik TM. et al. Prognostic relevance of lymph node ratio following pancreaticoduodenectomy for pancreatic cancer. Surgery 2007; 141 (05) 610-618
• 281 Prenzel KL. et al. Lymph node size and metastatic infiltration in adenocarcinoma of the pancreatic head. Eur J Surg Oncol 2010; 36 (10) 993-996
• 282 Riediger H. et al. The lymph node ratio is the strongest prognostic factor after resection of pancreatic cancer. J Gastrointest Surg 2009; 13 (07) 1337-1344
• 283 Showalter TN. et al. The Influence of Total Nodes Examined, Number of Positive Nodes, and Lymph Node Ratio on Survival after Surgical Resection and Adjuvant Chemoradiation for Pancreatic Cancer: A Secondary Analysis of RTOG 9704. Int J Radiat Oncol Biol Phys 2010.
• 284 Slidell MB. et al. Impact of total lymph node count and lymph node ratio on staging and survival after pancreatectomy for pancreatic adenocarcinoma: a large, population-based analysis. Ann Surg Oncol 2008; 15 (01) 165-174
• 285 Chen S. et al. Robot-assisted laparoscopic versus open middle pancreatectomy: short-term results of a randomized controlled trial. Surgical Endoscopy 2017; 31 (02) 962-971
• 286 Xourafas D, Ashley SW, Clancy TE. Comparison of Perioperative Outcomes between Open, Laparoscopic, and Robotic Distal Pancreatectomy: an Analysis of 1815 Patients from the ACS-NSQIP Procedure-Targeted Pancreatectomy Database. J Gastrointest Surg 2017; 21 (09) 1442-1452
• 287 Mirkin KA. et al. Minimally invasive surgical approaches offer earlier time to adjuvant chemotherapy but not improved survival in resected pancreatic cancer. Surg Endosc 2018; 32 (05) 2387-2396
• 288 Kutlu OC. et al. Open Pancreaticoduodenectomy Case Volume Predicts Outcome of Laparoscopic Approach: A Population-based Analysis. Ann Surg 2018; 267 (03) 552-560
• 289 Kauffmann EF. et al. A propensity score-matched analysis of robotic versus open pancreatoduodenectomy for pancreatic cancer based on margin status. Surgical Endoscopy 2019; 33 (01) 234-242
• 290 Boggi U. et al. Robotic-Assisted Pancreatic Resections. World J Surg 2016; 40 (10) 2497-2506
• 291 Adam MA. et al. Defining a Hospital Volume Threshold for Minimally Invasive Pancreaticoduodenectomy in the United States. JAMA Surg 2017; 152 (04) 336-342
• 292 Abu Hilal M. et al. Laparoscopic versus open distal pancreatectomy: a clinical and cost-effectiveness study. Surg Endosc 2012; 26 (06) 1670-1674
• 293 Raoof M. et al. Propensity score-matched comparison of oncological outcomes between laparoscopic and open distal pancreatic resection. The British journal of surgery 2018; 105 (05) 578-586
• 294 Fujita T. et al. Evaluation of the prognostic factors and significance of lymph node status in invasive ductal carcinoma of the body or tail of the pancreas. Pancreas 2010; 39 (01) e48-e54
• 295 Shimada K. et al. Intrapancreatic nerve invasion as a predictor for recurrence after pancreaticoduodenectomy in patients with invasive ductal carcinoma of the pancreas. Pancreas 2011; 40 (03) 464-468
• 296 Zacharias T. et al. Impact of lymph node involvement on long-term survival after R0 pancreaticoduodenectomy for ductal adenocarcinoma of the pancreas. J Gastrointest Surg 2007; 11 (03) 350-356
• 297 Wasif N. et al. Impact of tumor grade on prognosis in pancreatic cancer: Should we include grade in AJCC staging?. Annals of Surgical Oncology 2010; 17 (09) 2312-2320
• 298 Boggi U. et al. Prognostic implications of tumor invasion or adhesion to peripancreatic vessels in resected pancreatic cancer. Surgery 2009; 146 (05) 869-881
• 299 Kurahara H. et al. Impact of lymph node micrometastasis in patients with pancreatic head cancer. World J Surg 2007; 31 (03) 483-490
• 300 Menon KV. et al. Impact of margin status on survival following pancreatoduodenectomy for cancer: the Leeds Pathology Protocol (LEEPP). HPB (Oxford) 2009; 11 (01) 18-24
• 301 Fatima J. et al. Pancreatoduodenectomy for ductal adenocarcinoma: implications of positive margin on survival. Arch Surg 2010; 145 (02) 167-172
• 302 Lee SE. et al. Clinical implications of immunohistochemically demonstrated lymph node micrometastasis in resectable pancreatic cancer. J Korean Med Sci 2011; 26 (07) 881-885
• 303 Mitsunaga S. et al. Detail histologic analysis of nerve plexus invasion in invasive ductal carcinoma of the pancreas and its prognostic impact. Am J Surg Pathol 2007; 31 (11) 1636-1644
• 304 Kanda M. et al. Invasion of the splenic artery is a crucial prognostic factor in carcinoma of the body and tail of the pancreas. Ann Surg 2010; 251 (03) 483-487
• 305 Hishinuma S. et al. Patterns of recurrence after curative resection of pancreatic cancer, based on autopsy findings. J Gastrointest Surg 2006; 10 (04) 511-518
• 306 Oettle H. et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA 2007; 297 (03) 267-277
• 307 Ueno H. et al. A randomised phase III trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer: Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer. Br J Cancer 2009; 101 (06) 908-915
• 308 Neoptolemos JP. et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 2004; 350 (12) 1200-1210
• 309 Stocken DD. et al. Meta-analysis of randomised adjuvant therapy trials for pancreatic cancer. Br J Cancer 2005; 92 (08) 1372-1381
• 310 Neoptolemos JP. et al. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA 2010; 304 (10) 1073-1081
• 311 Yoshitomi H. et al. A randomized phase II trial of adjuvant chemotherapy with uracil/tegafur and gemcitabine versus gemcitabine alone in patients with resected pancreatic cancer. Cancer 2008; 113 (09) 2448-2456
• 312 Neoptolemos JP. et al. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. The Lancet 2017; (no pagination)
• 313 Conroy T. et al. FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer. New England Journal of Medicine 2018; 379 (25) 2395-5406
• 314 Oettle H. et al. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. JAMA: Journal of the American Medical Association 2013; 310 (14) 1473-1481
• 315 Sinn M. et al. CONKO-005: Adjuvant Chemotherapy With Gemcitabine Plus Erlotinib Versus Gemcitabine Alone in Patients After R0 Resection of Pancreatic Cancer: A Multicenter Randomized Phase III Trial. Journal of Clinical Oncology 2017; 35 (29) 3330-3337
• 316 Valle JW. et al. Optimal duration and timing of adjuvant chemotherapy after definitive surgery for ductal adenocarcinoma of the pancreas: Ongoing lessons from the ESPAC-3 study. Journal of Clinical Oncology 2014; 32 (06) 504-512
• 317 Saeed H. et al. Defining the optimal timing of adjuvant therapy for resected pancreatic adenocarcinoma: A statewide cancer registry analysis. Journal of Surgical Oncology 2016; 114 (04) 451-455
• 318 Sun W. et al. Proposing the lymphatic target volume for elective radiation therapy for pancreatic cancer: a pooled analysis of clinical evidence. Radiat Oncol 2010; 5: 28
• 319 Kalser MH, Ellenberg SS. Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg 1985; 120 (08) 899-903
• 320 Smeenk HG. et al. Long-term survival and metastatic pattern of pancreatic and periampullary cancer after adjuvant chemoradiation or observation: long-term results of EORTC trial 40891. Ann Surg 2007; 246 (05) 734-740
• 321 Morak MJ. et al. Adjuvant intra-arterial chemotherapy and radiotherapy versus surgery alone in resectable pancreatic and periampullary cancer: a prospective randomized controlled trial. Ann Surg 2008; 248 (06) 1031-1041
• 322 Neoptolemos JP. et al. Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. Lancet 2001; 358: 1576-1585
• 323 Carter R. et al. Longitudinal quality of life data can provide insights on the impact of adjuvant treatment for pancreatic cancer-Subset analysis of the ESPAC-1 data. Int J Cancer 2009; 124 (12) 2960-2965
• 324 Klinkenbijl JH. et al. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg 1999; 230 (06) 776-782
• 325 Van Laethem JL. et al. Adjuvant gemcitabine alone versus gemcitabine-based chemoradiotherapy after curative resection for pancreatic cancer: a randomized EORTC-40013-22012/FFCD-9203/GERCOR phase II study. J Clin Oncol 2010; 28 (29) 4450-4456
• 326 Regine WF. et al. Fluorouracil-based chemoradiation with either gemcitabine or fluorouracil chemotherapy after resection of pancreatic adenocarcinoma: 5-year analysis of the U.S. Intergroup/RTOG 9704 phase III trial. Ann Surg Oncol 2011; 18 (05) 1319-1326
• 327 Reni M. et al. Adjuvant PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) or gemcitabine followed by chemoradiation in pancreatic cancer: A randomized phase II trial. Annals of Surgical Oncology 2012; 19 (07) 2256-2263
• 328 Yeo CJ. et al. Pancreaticoduodenectomy for pancreatic adenocarcinoma: postoperative adjuvant chemoradiation improves survival. A prospective, single-institution experience. Ann Surg 1997; 225 (05) 621-633
• 329 Bosset JF. et al. Conventional external irradiation alone as adjuvant treatment in resectable pancreatic cancer: results of a prospective study. Radiother Oncol 1992; 24 (03) 191-194
• 330 Brunner TB. et al. Definition of elective lymphatic target volume in ductal carcinoma of the pancreatic head based on histopathologic analysis. Int J Radiat Oncol Biol Phys 2005; 62 (04) 1021-1029
• 331 Herman JM. et al. Analysis of fluorouracil-based adjuvant chemotherapy and radiation after pancreaticoduodenectomy for ductal adenocarcinoma of the pancreas: results of a large, prospectively collected database at the Johns Hopkins Hospital. J Clin Oncol 2008; 26 (21) 3503-3510
• 332 Butturini G. et al. Influence of resection margins and treatment on survival in patients with pancreatic cancer: meta-analysis of randomized controlled trials. Arch Surg 2008; 143 (01) 75-83
• 333 Andriulli A. et al. Neoadjuvant/preoperative gemcitabine for patients with localized pancreatic cancer: a meta-analysis of prospective studies. Ann Surg Oncol 2011; 19 (05) 1644-1662
• 334 Assifi MM. et al. Neoadjuvant therapy in pancreatic adenocarcinoma: a meta-analysis of phase II trials. Surgery 2011; 150 (03) 466-473
• 335 Bradley A, Van Der Meer R. Upfront Surgery versus Neoadjuvant Therapy for Resectable Pancreatic Cancer: Systematic Review and Bayesian Network Meta-analysis. Scientific reports 2019; 9 (01) 4354
• 336 Gillen S. et al. Preoperative/neoadjuvant therapy in pancreatic cancer: A systematic review and meta-analysis of response and resection percentages. PLoS Medicine 2010; 7(4).
• 337 Palmer DH. et al. A randomized phase 2 trial of neoadjuvant chemotherapy in resectable pancreatic cancer: gemcitabine alone versus gemcitabine combined with cisplatin. Ann Surg Oncol 2007; 14 (07) 2088-2096
• 338 Versteijne E. et al. Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III PREOPANC Trial. J Clin Oncol 2020;
• 339 Barbier L. et al. Pancreatic head resectable adenocarcinoma: preoperative chemoradiation improves local control but does not affect survival. HPB (Oxford) 2011; 13 (01) 64-69
• 340 Takahashi S. et al. Borderline resectable pancreatic cancer: rationale for multidisciplinary treatment. J Hepatobiliary Pancreat Sci 2011; 18 (04) 567-574
• 341 Chun YS. et al. Significance of pathologic response to preoperative therapy in pancreatic cancer. Ann Surg Oncol 2011; 18 (13) 3601-3607
• 342 Heinrich S. et al. Neoadjuvant chemotherapy generates a significant tumor response in resectable pancreatic cancer without increasing morbidity: results of a prospective phase II trial. Ann Surg 2008; 248 (06) 1014-1022
• 343 Lutfi W. et al. Perioperative chemotherapy is associated with a survival advantage in early stage adenocarcinoma of the pancreatic head. Surgery (United Kingdom) 2016; 160 (03) 714-724
• 344 Czosnyka NM, Borgert AJ, Smith TJ. Pancreatic adenocarcinoma: effects of neoadjuvant therapy on post-pancreatectomy outcomes – an American College of Surgeons National Surgical Quality Improvement Program targeted variable review. HPB 2017; 19 (10) 927-932
• 345 de Geus SWL. et al. Neoadjuvant therapy versus upfront surgery for resected pancreatic adenocarcinoma: A nationwide propensity score matched analysis. Surgery (United States) 2017; 161 (03) 592-601
• 346 Mirkin KA, Hollenbeak CS, Wong J. Survival impact of neoadjuvant therapy in resected pancreatic cancer: A Prospective Cohort Study involving 18,332 patients from the National Cancer Data Base. International Journal of Surgery 2016; 34: 96-102
• 347 Versteijne E. et al. Meta-analysis comparing upfront surgery with neoadjuvant treatment in patients with resectable or borderline resectable pancreatic cancer. The British journal of surgery 2018; 105 (08) 946-958
• 348 Truty MJ. et al. Factors Predicting Response, Perioperative Outcomes, and Survival Following Total Neoadjuvant Therapy for Borderline/Locally Advanced Pancreatic Cancer. Annals of surgery 2019.
• 349 Mokdad AA. et al. Neoadjuvant Therapy Followed by Resection Versus Upfront Resection for Resectable Pancreatic Cancer: A Propensity Score Matched Analysis. Journal of Clinical Oncology 2017; 35 (05) 515-522
• 350 de Geus SWL. et al. Neoadjuvant therapy versus upfront surgical strategies in resectable pancreatic cancer: A Markov decision analysis. European Journal of Surgical Oncology 2016; 42 (10) 1552-1560
• 351 Franko J. et al. Chemotherapy and radiation components of neoadjuvant treatment of pancreatic head adenocarcinoma: Impact on perioperative mortality and long-term survival. European Journal of Surgical Oncology 2017; 43 (02) 351-357
• 352 Fisher AV. et al. The Impact of Hospital Neoadjuvant Therapy Utilization on Survival Outcomes for Pancreatic Cancer. Annals of Surgical Oncology 2018; 25 (09) 2661-2668
• 353 Hammel P. et al. Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib: The LAP07 Randomized Clinical Trial. JAMA: Journal of the American Medical Association 2016; 315 (17) 1844-1853
• 354 Jang JY. et al. Oncological Benefits of Neoadjuvant Chemoradiation With Gemcitabine Versus Upfront Surgery in Patients With Borderline Resectable Pancreatic Cancer: A Prospective, Randomized, Open-label, Multicenter Phase 2/3 Trial. Annals of surgery 2018; 268 (02) 215-222
• 355 Chen X. et al. Neoadjuvant radiation followed by resection versus upfront resection for locally advanced pancreatic cancer patients: a propensity score matched analysis. Oncotarget 2017; 8 (29) 47831-47840
• 356 Gemenetzis G. et al. Survival in Locally Advanced Pancreatic Cancer After Neoadjuvant Therapy and Surgical Resection. Annals of surgery 2018.
• 357 Hackert T. et al. Locally advanced pancreatic cancer: Neoadjuvant therapy with folfirinox results in resectability in 60% of the patients. Annals of surgery 2016; 264 (03) 457-461
• 358 Hartwig W. et al. CA19-9 in potentially resectable pancreatic cancer: Perspective to adjust surgical and perioperative therapy. Annals of Surgical Oncology 2013; 20 (07) 2188-2196
• 359 Nagakawa Y. et al. Clinical Impact of Neoadjuvant Chemotherapy and Chemoradiotherapy in Borderline Resectable Pancreatic Cancer: Analysis of 884 Patients at Facilities Specializing in Pancreatic Surgery. Annals of Surgical Oncology 2019;
• 360 Pietrasz D. et al. How Does Chemoradiotherapy Following Induction FOLFIRINOX Improve the Results in Resected Borderline or Locally Advanced Pancreatic Adenocarcinoma? An AGEO-FRENCH Multicentric Cohort. Annals of Surgical Oncology 2019; 26 (01) 109-117
• 361 Kasperk R. et al. Intraoperative radiotherapy for pancreatic carcinoma. Br J Surg 1995; 82 (09) 1259-1261
• 362 Reni M. et al. Effect on local control and survival of electron beam intraoperative irradiation for resectable pancreatic adenocarcinoma. Int J Radiat Oncol Biol Phys 2001; 50 (03) 651-658
• 363 Yamaguchi K. et al. ERT following IORT improves survival of patients with resectable pancreatic cancer. Hepatogastroenterology 2005; 52 (64) 1244-1249
• 364 Messick C. et al. Early experience with intraoperative radiotherapy in patients with resected pancreatic adenocarcinoma. Am J Surg 2008; 195 (03) 308-311
• 365 Showalter TN. et al. Does intraoperative radiation therapy improve local tumor control in patients undergoing pancreaticoduodenectomy for pancreatic adenocarcinoma? A propensity score analysis. Ann Surg Oncol 2009; 16 (08) 2116-2122
• 366 Ruano-Ravina A, Almazan Ortega R, Guedea F. Intraoperative radiotherapy in pancreatic cancer: a systematic review. Radiother Oncol 2008; 87 (03) 318-325
• 367 Zygogianni GA. et al. Intraoperative radiation therapy on pancreatic cancer patients: a review of the literature. Minerva Chir 2011; 66 (04) 361-369
• 368 Nagai S. et al. Prognostic implications of intraoperative radiotherapy for unresectable pancreatic cancer. Pancreatology 2011; 11 (01) 68-75
• 369 Karasawa K. et al. Efficacy of novel hypoxic cell sensitiser doranidazole in the treatment of locally advanced pancreatic cancer: long-term results of a placebo-controlled randomised study. Radiother Oncol 2008; 87 (03) 326-330
• 370 Suker M. et al. FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. Lancet Oncology 2016; 17 (06) 801-810
• 371 Bernard V. et al. Circulating Nucleic Acids Are Associated With Outcomes of Patients With Pancreatic Cancer. Gastroenterology 2019; 156 (01) 108
• 372 Tsai S. et al. Importance of Normalization of CA19-9 Levels Following Neoadjuvant Therapy in Patients With Localized Pancreatic Cancer. Ann Surg 2020; 271 (04) 740-747
• 373 Akita H. et al. FDG-PET predicts treatment efficacy and surgical outcome of pre-operative chemoradiation therapy for resectable and borderline resectable pancreatic cancer. European Journal of Surgical Oncology 2017; 43 (06) 1061-1067
• 374 Aldakkak M. et al. Pre-treatment carbohydrate antigen 19-9 does not predict the response to neoadjuvant therapy in patients with localized pancreatic cancer. HPB : the official journal of the International Hepato Pancreato Biliary Association 2015; 17 (10) 942-952
• 375 Aoki S. et al. Decreased serum carbohydrate antigen 19-9 levels after neoadjuvant therapy predict a better prognosis for patients with pancreatic adenocarcinoma: A multicenter case-control study of 240 patients. BMC Cancer 2019; 19 (01) 252
• 376 Mallinson CN. et al. Chemotherapy in pancreatic cancer: results of a controlled, prospective, randomised, multicentre trial. Br Med J 1980; 281: 1589-1591
• 377 Palmer KR. et al. Chemotherapy prolongs survival in inoperable pancreatic carcinoma. Br J Surg 1994; 81 (06) 882-885
• 378 Glimelius B. et al. Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol 1996; 7 (06) 593-600
• 379 Yip D. et al. Chemotherapy and radiotherapy for inoperable advanced pancreatic cancer. Cochrane Database Syst Rev 2006; 3: CD002093
• 380 Burris 3rd HA. et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997; 15 (06) 2403-2413
• 381 Sohal DPS. et al. Metastatic Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline. Journal of Clinical Oncology 2016; 34 (23) 2784-2796
• 382 Moore MJ. et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada Clinical Trials Group. Journal of Clinical Oncology 2007; 25 (15) 1960-1966
• 383 Conroy T. et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011; 364 (19) 1817-1825
• 384 Von Hoff DD. et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. New England Journal of Medicine 2013; 369 (18) 1691-1703
• 385 Sohal DPS. et al. Metastatic Pancreatic Cancer: ASCO Clinical Practice Guideline Update. Journal of Clinical Oncology 2018; 36 (24) 2545-2556
• 386 Poplin E. et al. Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009; 3778-3785
• 387 National Institute for, H. and E. Care, Pancreatic cancer in adults: diagnosis and management. NICE Guideline NG85. London: NICE: 2018
• 388 Li Q. et al. Efficacy and safety of gemcitabine-fluorouracil combination therapy in the management of advanced pancreatic cancer: A meta-analysis of randomized controlled trials. PLoS ONE 2014; 9 (08) e104346
• 389 Tu C. et al. An Updated Meta-analysis and System Review:is Gemcitabine+Fluoropyrimidine in Combination a Better Therapy Versus Gemcitabine Alone for Advanced and Unresectable Pancreatic Cancer?. Asian Pacific journal of cancer prevention : APJCP 2015; 16 (14) 5681-5686
• 390 Chin V. et al. Chemotherapy and radiotherapy for advanced pancreatic cancer. Cochrane Database of Systematic Reviews 2018; 2018 (03) CD011044
• 391 Van Cutsem E. et al. Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. Journal of Clinical Oncology 2009; 27 (13) 2231-2237
• 392 Heinemann V. et al. Gemcitabine plus erlotinib followed by capecitabine versus capecitabine plus erlotinib followed by gemcitabine in advanced pancreatic cancer: final results of a randomised phase 3 trial of the “Arbeitsgemeinschaft Internistische Onkologie” (AIO-PK0104). Gut 2013; 62 (05) 751-759
• 393 Eltawil KM, Renfrew PD, Molinari M. Meta-analysis of Phase III randomized trials of molecular targeted therapies for advanced pancreatic cancer. HPB, 2012.
• 394 Ciliberto D. et al. Role of gemcitabine-based combination therapy in the management of advanced pancreatic cancer: a meta-analysis of randomised trials. Eur J Cancer 2013; 49 (03) 593-603
• 395 Tong M. et al. Efficacy and safety of gemcitabine plus anti-angiogenesis therapy for advanced pancreatic cancer: A systematic review and meta-analysis of clinical randomized phase III trials. Journal of Cancer 2019; 10 (04) 968-978
• 396 OʼReilly EM. et al. Randomized, Multicenter, Phase II Trial of Gemcitabine and Cisplatin With or Without Veliparib in Patients With Pancreas Adenocarcinoma and a Germline BRCA/PALB2 Mutation. J Clin Oncol 2020; 38 (13) 1378-1388
• 397 Park W. et al. Genomic Methods Identify Homologous Recombination Deficiency in Pancreas Adenocarcinoma and Optimize Treatment Selection. Clinical Cancer Research 2020; 26
• 398 Golan T. et al. Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer. The New England Journal of Medicine 2019;
• 399 Herman JM. et al. Phase 2 multi-institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma. Cancer (0008543X) 2015; 121 (07) 1128-1137
• 400 Ambe C. et al. A Meta-analysis of Randomized Clinical Trials of Chemoradiation Therapy in Locally Advanced Pancreatic Cancer. Journal of gastrointestinal cancer 2015; 46
• 401 Zhu CP. et al. Gemcitabine in the chemoradiotherapy for locally advanced pancreatic cancer: a meta-analysis. Radiother Oncol 2011; 99 (02) 108-113
• 402 Hurt CN. et al. Long-term results and recurrence patterns from SCALOP: a phase II randomised trial of gemcitabine- or capecitabine-based chemoradiation for locally advanced pancreatic cancer. Br J Cancer 2017; 116 (10) 1264-1270
• 403 Mercadante S. Pain treatment and outcomes for patients with advanced cancer who receive follow-up care at home. Cancer 1999; 85 (08) 1849-1858
• 404 Zech DF. et al. Validation of World Health Organization Guidelines for cancer pain relief: a 10-year prospective study. Pain 1995; 63 (01) 65-76
• 405 Marinangeli F. et al. Use of strong opioids in advanced cancer pain: a randomized trial. J Pain Symptom Manage 2004; 27 (05) 409-416
• 406 Grahm AL, Andren-Sandberg A. Prospective evaluation of pain in exocrine pancreatic cancer. Digestion 1997; 58 (06) 542-549
• 407 Caraceni A, Portenoy RK. Pain management in patients with pancreatic carcinoma. Cancer 1996; 78 (Suppl. 03) 639-653
• 408 Ross GJ. et al. Sonographically guided paracentesis for palliation of symptomatic malignant ascites. Am J Roentgenol 1989; 153 (06) 1309-1311
• 409 McNicol E. et al. Nonsteroidal anti-inflammatory drugs, alone or combined with opioids, for cancer pain: a systematic review. J Clin Oncol 2004; 22 (10) 1975-1992
• 410 Carr DB. et al. Evidence report on the treatment of pain in cancer patients. J Natl Cancer Inst Monogr 2004; 32: 23-31
• 411 Payne R. et al. Quality of life and cancer pain: satisfaction and side effects with transdermal fentanyl versus oral morphine. J Clin Oncol 1998; 16 (04) 1588-1593
• 412 De Conno F. et al. Role of rectal route in treating cancer pain: a randomized crossover clinical trial of oral versus rectal morphine administration in opioid-naive cancer patients with pain. J Clin Oncol 1995; 13 (04) 1004-1008
• 413 Cherny NI. The management of cancer pain. CA Cancer J Clin 2000; 50 (02) 70-116
• 414 Gilmer-Hill HS. et al. Intrathecal morphine delivered via subcutaneous pump for intractable pain in pancreatic cancer. Surg Neurol 1999; 51 (01) 6-11
• 415 Staats PS. et al. The effects of alcohol celiac plexus block, pain, and mood on longevity in patients with unresectable pancreatic cancer: a double-blind, randomized, placebo-controlled study. Pain Med 2001; 2 (01) 28-34
• 416 Eisenberg E, Carr DB, Chalmers TC. Neurolytic celiac plexus block for treatment of cancer pain: a meta-analysis. Anesth Analg 1995; 80 (02) 290-295
• 417 Stefaniak T. et al. A comparison of two invasive techniques in the management of intractable pain due to inoperable pancreatic cancer: neurolytic celiac plexus block and videothoracoscopic splanchnicectomy. Eur J Surg Oncol 2005; 31 (07) 768-773
• 418 Arends J. et al. ESPEN Guidelines on Enteral Nutrition: Non-surgical oncology. Clin Nutr 2006; 25 (02) 245-259
• 419 Arends J. et al. DGEM Leitlinie Enterale Ernährung: Onkologie. Akt Ernähr Med 2003; 28: 61-68
• 420 Bjelakovic G. et al. Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis. JAMA 2007; 297 (08) 842-857
• 421 Wigmore SJ. et al. Ibuprofen reduces energy expenditure and acute-phase protein production compared with placebo in pancreatic cancer patients. Br J Cancer 1995; 72 (01) 185-188
• 422 Gordon JN. et al. Thalidomide in the treatment of cancer cachexia: a randomised placebo controlled trial. Gut 2005; 54 (04) 540-545
• 423 Jatoi A. et al. Dronabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia: a North Central Cancer Treatment Group study. J Clin Oncol 2002; 20 (02) 567-573
• 424 Loprinzi CL. et al. Randomized comparison of megestrol acetate versus dexamethasone versus fluoxymesterone for the treatment of cancer anorexia/cachexia. J Clin Oncol 1999; 17 (10) 3299-3306
• 425 Moss AC, Morris E, Mac MathunaP. Palliative biliary stents for obstructing pancreatic carcinoma. Cochrane Database Syst Rev 2006; 1: CD004200
• 426 Hausegger KA. et al. Treatment of malignant biliary obstruction with polyurethane-covered Wallstents. Am J Roentgenol 1998; 170 (02) 403-408
• 427 Isayama H. et al. A prospective randomised study of "covered" versus "uncovered" diamond stents for the management of distal malignant biliary obstruction. Gut 2004; 53 (05) 729-734
• 428 Speer AG. et al. Randomised trial of endoscopic versus percutaneous stent insertion in malignant obstructive jaundice. Lancet 1987; 2: 57-62
• 429 Urbach DR. et al. Cohort study of surgical bypass to the gallbladder or bile duct for the palliation of jaundice due to pancreatic cancer. Ann Surg 2003; 237 (01) 86-93
• 430 DiFronzo LA, Egrari S, OʼConnell TX. Choledochoduodenostomy for palliation in unresectable pancreatic cancer. Arch Surg 1998; 133 (08) 820-825
• 431 Aranha GV, Prinz RA, Greenlee HB. Biliary enteric bypass for benign and malignant disease. Am Surg 1987; 53 (07) 403-406
• 432 Song HY. et al. A dual expandable nitinol stent: experience in 102 patients with malignant gastroduodenal strictures. J Vasc Interv Radiol 2004; 15 (12) 1443-1449
• 433 Kaw M. et al. Role of self-expandable metal stents in the palliation of malignant duodenal obstruction. Surg Endosc 2003; 17 (04) 646-650
• 434 Lillemoe KD. et al. Is prophylactic gastrojejunostomy indicated for unresectable periampullary cancer? A prospective randomized trial. Ann Surg 1999; 230 (03) 322-328
• 435 Smith TJ. et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 2006; 24 (19) 3187-3205
• 436 Rizzo JD. et al. Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. J Clin Oncol 2002; 20 (19) 4083-4107
• 437 Bokemeyer C. et al. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update. Eur J Cancer 2007; 43 (02) 258-270
• 438 Schuchter LM. et al. 2002 update of recommendations for the use of chemotherapy and radiotherapy protectants: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2002; 20 (12) 2895-2903
• 439 Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, D.K., AWMF). Entwicklung von leitlinienbasierten Qualitätsindikatoren. Methodenpapier für das Leitlinienprogramm Onkologie, Version 2.1. 2017 Available from: http://www.leitlinienprogramm-onkologie.de/methodik/informationen-zur-methodik/